retatrutide peptide obesity triple hormone receptor agonist glp-1 gip glucagon phase 2 nejm 2023 Medscape Exciting News! 🗞️ Retatrutide is

The scale cannot tell you if your vitamin D is deficient

Resveratrol and its methoxy-derivatives as modulators of DNA damage induced by ionising radiation

There's a lot to unpack, so we've structured our thoughts into three distinct sectionsfeel free to peruse the whole post or jump forward to specific areas of interest using the links below: We'll start by sharing our about where the innovation race is headingand what it means for the industry key insights and predictions From there, we'll overview (including key differentiators between major competitors Eli Lilly and Novo Nordisk) what the race has looked to date Finally, we'll go deep on the that will define the innovation race moving forward: five vectors of innovation GLP-1 innovation: Key insights and predictions GLP-1s are more than a blockbuster drug class, they signal a profound reordering of how chronic disease is managed, financed, and even understood

An overview of glp-1 agonists and recent cardiovascular outcomes trials